p. 3001−3008
2476-762X
Vol.19/No.11
p. 3009−3018
2476-762X
Vol.19/No.11
p. 3019−3025
2476-762X
Vol.19/No.11
p. 3027−3032
2476-762X
Vol.19/No.11
p. 3033−3038
2476-762X
Vol.19/No.11
p. 3039−3044
2476-762X
Vol.19/No.11
p. 3045−3052
2476-762X
Vol.19/No.11
p. 3053−3057
2476-762X
Vol.19/No.11
p. 3059−3063
2476-762X
Vol.19/No.11
p. 3065−3069
2476-762X
Vol.19/No.11
p. 3071−3075
2476-762X
Vol.19/No.11
p. 3077−3079
2476-762X
Vol.19/No.11
p. 3081−3086
2476-762X
Vol.19/No.11
p. 3087−3092
2476-762X
Vol.19/No.11
p. 3093−3098
2476-762X
Vol.19/No.11
p. 3099−3103
2476-762X
Vol.19/No.11
p. 3105−3109
2476-762X
Vol.19/No.11
p. 3111−3115
2476-762X
Vol.19/No.11
p. 3117−3122
2476-762X
Vol.19/No.11
p. 3123−3129
2476-762X
Vol.19/No.11
1,000 in 8 cases, while 30 had low and 7 high MRD(both >0.01) at day 35 of treatment. The median MFI for LAIR-1 expression in control cases was 8.2 (range 7.76-11.69)and in ALL cases 4.02 (range 0.56 to 11.87), with 74% (n-31) of ALL cases showing reduced LAIR-1 expression.However, no significant correlations were found between standard ALL risk factors and LAIR-1 expression. Out of42 patients, 4 died during induction treatment and one exited therapy, 60% (n-3/5) of these featuring low expressionof LAIR-1. Also ALL patients with low LAIR-1 expression had t (12;21), t (1;19) and t (4;11) translocations in 2, 4and 1 samples, respectively, but none had t (9;22). Of those with high LAIR-1 expression, 2 had t (9;22) (MFIs-14.43and 11.87). Conclusions: This pilot study of LAIR-1expression in ALL suggests low expression of the inhibitorymolecule in leukemic cells. However, the findings need to be confirmed with larger cohort, along with studies focusingon pathophysiological roles in leukemic clone survival and escape from the immune system.]]>
p. 3131−3135
2476-762X
Vol.19/No.11
p. 3137−3146
2476-762X
Vol.19/No.11
p. 3147−3152
2476-762X
Vol.19/No.11
p. 3153−3159
2476-762X
Vol.19/No.11
p. 3161−3166
2476-762X
Vol.19/No.11
p. 3167−3174
2476-762X
Vol.19/No.11
p. 3175−3178
2476-762X
Vol.19/No.11
p. 3179−3185
2476-762X
Vol.19/No.11
p. 3187−3192
2476-762X
Vol.19/No.11
p. 3193−3202
2476-762X
Vol.19/No.11
p. 3203−3209
2476-762X
Vol.19/No.11
p. 3211−3216
2476-762X
Vol.19/No.11
p. 3217−3223
2476-762X
Vol.19/No.11
p. 3225−3231
2476-762X
Vol.19/No.11
p. 3233−3236
2476-762X
Vol.19/No.11
p. 3237−3244
2476-762X
Vol.19/No.11
p. 3245−3250
2476-762X
Vol.19/No.11
p. 3251−3256
2476-762X
Vol.19/No.11
p. 3257−3263
2476-762X
Vol.19/No.11
p. 3265−3270
2476-762X
Vol.19/No.11
p. 3271−3277
2476-762X
Vol.19/No.11
p. 3279−3286
2476-762X
Vol.19/No.11
p. 3287−3294
2476-762X
Vol.19/No.11
p. 3295−3299
2476-762X
Vol.19/No.11
6, presence of varices were independent risk factors of having VB inHCC patients (OR=7.59, 95%CI=1.13-50.88, p=0.037; OR=5.07, 95%CI=1.08-23.76, p=0.039; OR=23.51, 95%CI=4.71-117.35, p<0.001, respectively). In HCC patients with VB, 1-year and 2.5-year survival rates were 56.6% and 28.3%.Conclusions: HCC patients with ascites, Child-Pugh score>6 and presence of varices might be important predictivefactors of VB. Having VB were greatly impact to the survival rate of HCC patients. Clinical suspicion and regularsurveillance of VB in HCC patients at risk could improve treatment outcomes.]]>
p. 3301−3305
2476-762X
Vol.19/No.11